The objective of this study was to evaluate the impact of allodynia on treatment outcomes in
the patients with acute migraine treated in the “Act when Mild”(AwM) study. AwM, a …

A meta-analysis of pooled individual patient data from four randomized, placebo-controlled,
double-blind trials comparing several doses of almotriptan (n= 1908) with placebo (n= 386) …

Objective.—To determine whether treatment of migraine with almotriptan, when pain
intensity is mild, improves 1‐and 2‐hour pain‐free and sustained pain‐free rates compared …

Objective.—Evaluate the effect of almotriptan on sustained pain‐free outcome in patients
with acute migraine. Methods.—Three randomized, double‐blind, placebo‐controlled trials …

In this double-blind study, the efficacy and tolerability of a single dose of almotriptan (6.25 or
12.5 mg) was compared with placebo in the treatment of three consecutive migraine attacks …

Almotriptan is a serotonin (5-hydroxytryptamine) 1B/1D receptor agonist (triptan) that has
shown consistent efficacy in the acute treatment of migraine with excellent tolerability. It is an …

In a large observational general practice study (the Standardized Study with Almotriptan in
Early Treatment of Migraine [START]), 12.5 mg almotriptan administered within 1 h of pain …

In this randomized, double‐blind, crossover clinical trial, adult patients treated two migraine
attacks: one with almotriptan 12.5 mg and the other with ergotamine 2 mg plus caffeine 200 …

The study was designed to compare the response to almotriptan in migraine patients who
take medication early in the course of the attack with that when medication is taken after pain …

Objective.—To evaluate the relationship between treatment outcomes and allodynia‐
associated symptoms (AAS) at the time of treatment with almotriptan. Methods.—Analyses …